PODCAST

CME

ReachMD

science & medicine medicine

All Episodes

00:00:00

Clinical and Safety Outcomes from the LIGHTSITE III...

CME ·

2025/09/16

Faculty: David Boyer, MD Faculty: Diana V. Do, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Real-World Evidence of Photobiomodulation Efficacy in...

CME ·

2025/09/16

Faculty: Marion Munk, MD, Ph.D Faculty: David Boyer, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Sustaining Visual Benefits of Photobiomodulation in...

CME ·

2025/09/16

00:00:00

Patient-Centered Care and Integration of...

CME ·

2025/09/16

Faculty: Diana V. Do, MD Faculty: Marion Munk, MD, Ph.D This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Integration of Photobiomodulation Therapy into the...

CME ·

2025/09/16

Faculty: David Boyer, MD Faculty: Marion Munk, MD, Ph.D This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Best Practices for Optimized Photobiomodulation...

CME ·

2025/09/16

Faculty: Marion Munk, MD, Ph.D Faculty: Diana V. Do, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Anatomical Outcomes from the LIGHTSITE III Trial

CME ·

2025/09/16

Faculty: Diana V. Do, MD Faculty: David Boyer, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

CETP Inhibition with Obicetrapib: Implications for...

CME ·

2025/09/02

Host: Stephen Nicholls, FRACP, FACC, FESC, FAHA This program is intended for health care professionals only. Dr. Stephen Nicholls reveals new data on obicetrapib— showing promise in reducing cardiovascular events.

00:00:00

Emerging Therapies for Acute HAE: New Target, New...

CME ·

2025/08/11

Guest: Anna Valerieva Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical

00:00:00

Breakthrough Attacks: Why Prophylaxis Isn’t Always...

CME ·

2025/08/11

Host: Dr. Danny Cohn Guest: Dr. Thomas Buttgereit Guest: Anna Valerieva Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all

00:00:00

From Theory to Practice: Real-World Challenges in...

CME ·

2025/08/11

Host: Dr. Danny Cohn Guest: Dr. Thomas Buttgereit Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of

00:00:00

How to Build A Multidisciplinary Team in HAE to...

CME ·

2025/08/11

00:00:00

The Personal Touch: Advancing Personalized Treatment...

CME ·

2025/08/11

Guest: Dr. Thomas Buttgereit Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is

00:00:00

Prophylaxis Reimagined: Overcoming Challenges in...

CME ·

2025/08/11

00:00:00

How to Build A Multidisciplinary Team in HAE to...

CME ·

2025/08/11

00:00:00

Challenges in the Management of Difficult-to-Treat HAE

CME ·

2025/08/11

Guest: Dr. Thomas Buttgereit Guest: Anna Valerieva Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of

00:00:00

Next-Generation Therapies for Long-Term Prophylactic...

CME ·

2025/08/11

Host: Dr. Danny Cohn Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to

00:00:00

Optimizing Acute Treatment in the Era of Breakthrough...

CME ·

2025/08/11

00:00:00

Identifying a Key Cause of Hard to Control Diabetes

CME ·

2025/08/01

Host: Stephen Brunton, MD, FAAFP, CDCES Guest: John Buse, MD, PhD Guest: Jennifer Goldman, PharmD, CDCES, BC-ADM-FCCP Guest: Eden Miller, DO, D-ACD, D-ABOM The diagnosis of hypercortisolism is often delayed or missed, especially in primary care settings, leading to detrimental consequences for patients, such as unnecessary morbidity and mortality. Recent data suggest that the prevalence of hypercortisolism is far higher than previously estimated. Clinicians need to be

00:00:00

MET and Other Emerging Targets in Metastatic NSCLC

CME ·

2025/07/31

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and

299 results

CME

All Episodes

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe